tirzepatide blindness risk Zepbound Lawsuit [2026 Update] Could Ozempic and Wegovy Be

That changed in 2025 with the publication of SURMOUNT-5, the first randomized head-to-head trial, published in the New England Journal of Medicine

According to the FDA, Tirzepatide is more effective at lowering blood sugar and weight loss in type 2 diabetes patients than Ozempic, an injected GLP-1 receptor agonist, or two commonly used forms of insulin when used in this setting

Wegovy (semaglutide) is manufactured by Novo Nordisk

Avoiding physical activity Exercise helps maintain muscle mass and supports overall health during weight loss

Understanding the timeline for tirzepatide's effects requires distinguishing between different therapeutic outcomes, as glucose control and weight loss follow somewhat different trajectories